<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Kawasaki Disease - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-name-link {
            color: inherit;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
        }

        .item-name-link:hover {
            text-decoration-thickness: 2px;
        }

        .missing-disease-name {
            color: #991b1b;
            border-bottom: 1px dotted #dc2626;
        }

        .curation-gap-badge {
            display: inline-flex;
            align-items: center;
            margin-left: 8px;
            padding: 2px 8px;
            border-radius: 999px;
            font-size: 0.72rem;
            font-weight: 700;
            letter-spacing: 0.01em;
            text-transform: uppercase;
            background: #fef2f2;
            border: 1px solid #fecaca;
            color: #b91c1c;
            vertical-align: middle;
        }

        .missing-ontology-link {
            color: #b91c1c !important;
            text-decoration: underline dotted;
            text-underline-offset: 2px;
        }

        .dismech-inline-link {
            margin-left: 6px;
            font-size: 0.78rem;
            font-weight: 600;
            color: #0369a1;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
            white-space: nowrap;
        }

        .dismech-inline-link:hover {
            text-decoration-thickness: 2px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Kawasaki Disease</span>
        </nav>

        <header class="page-header">
            <h1>Kawasaki Disease</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Pediatric Condition</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0012727" target="_blank">
                        MONDO:0012727
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Vasculitis</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Kawasaki Disease is a condition in children that involves inflammation of blood vessels throughout the body and is characterized by fever, rash, and other symptoms.
            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">11</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">21</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">cardiovascular disorder</span>
                    
                    <span class="tag tag-classification">immune system disorder</span>
                    
                </div>
            </div>
            
            
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Vascular Inflammation</div>
                
                <div class="item-desc">Widespread inflammation of medium-sized arteries, including coronary arteries.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        vascular endothelial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000071" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        neutrophil
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000775" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        monocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000576" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        macrophage
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000235" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        endothelial cell activation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0042118" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        leukocyte adhesion to vascular endothelial cell
                        
                        <a href="http://purl.obolibrary.org/obo/GO_1904996" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        inflammatory response
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        coronary artery
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001621" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        artery wall
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0035965" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23188196" target="_blank">PMID:23188196</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Kawasaki disease (KD) is considered to be a kind of systemic vasculitis syndrome. It most frequently affects infants and young children and primarily invades medium-sized muscular arteries, including the coronary arteries."</div>
                
                
                <div class="evidence-explanation">The literature confirms that Kawasaki disease involves widespread inflammation of medium-sized arteries, including coronary arteries.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31599798" target="_blank">PMID:31599798</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Kawasaki disease is a childhood vasculitis of unknown origin, whose major complication is the development of coronary artery aneurysms (CAA)."</div>
                
                
                <div class="evidence-explanation">The literature supports that Kawasaki disease leads to vascular inflammation and aneurysm formation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27090101" target="_blank">PMID:27090101</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Coronary angiography showed multiple aneurysms which suggested sequelae of misdiagnosed Kawasaki disease."</div>
                
                
                <div class="evidence-explanation">The case report indicates that Kawasaki disease can lead to aneurysm formation as a result of vascular inflammation.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Immune Response Dysregulation</div>
                
                <div class="item-desc">An abnormal immune response leading to vessel wall damage and inflammation.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        CD8-positive, alpha-beta T cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000625" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        T-helper 17 cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000899" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        regulatory T cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000815" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        plasmablast
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000980" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        plasma cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000786" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        dendritic cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000451" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        NLRP3 inflammasome complex assembly
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0072559" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        interleukin-1 beta production
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0032611" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        tumor necrosis factor production
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0032640" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        interleukin-17 production
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0032620" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        calcium ion transmembrane transport
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0070588" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        T cell activation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0042110" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        complement activation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006956" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34890998" target="_blank">PMID:34890998</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Increasing evidence shows that the pathogenesis of Kawasaki disease (KD) is caused by abnormal and unbalanced innate and adaptive immune responses."</div>
                
                
                <div class="evidence-explanation">The literature supports the statement that Kawasaki Disease is characterized by immune response dysregulation leading to vessel wall damage and inflammation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30183655" target="_blank">PMID:30183655</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Kawasaki disease (KD) is a vasculitis that is part of systemic vasculitis syndrome. It affects medium-sized vessels and is characterized by hypercytokinemia."</div>
                
                
                <div class="evidence-explanation">This reference supports that KD involves immune dysregulation leading to vessel wall damage.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30619331" target="_blank">PMID:30619331</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Others have favored an autoreactive hypothesis that KD is triggered by an antigen that shares homology with structures in the vascular wall, and molecular mimicry resulting in an immune response directed to that tissue."</div>
                
                
                <div class="evidence-explanation">This supports the notion of an abnormal immune response leading to vessel wall damage in KD.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Vascular_Inflammation[&#34;Vascular Inflammation&#34;]
    Aneurysm_Formation[&#34;Aneurysm Formation&#34;]

    Vascular_Inflammation --&gt; Aneurysm_Formation

    style Vascular_Inflammation fill:#dbeafe
    style Aneurysm_Formation fill:#fef3c7</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">11</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Blood<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Cardiovascular<span class="pill-count">(4)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Immune<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Metabolism<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-5">Other<span class="pill-count">(4)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Blood
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Thrombocytosis
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001894" target="_blank">
                                Thrombocytosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001894)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Often appears 1-2 weeks after onset</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33527178" target="_blank">PMID:33527178</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In Kawasaki disease (KD), thrombocytosis is commonly found in the subacute phase."</div>
                
                
                <div class="evidence-explanation">Thrombocytosis is a common finding during the subacute phase of KD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/6833960" target="_blank">PMID:6833960</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The second, subacute, phase begins with a decline of the acute findings and proceeds with desquamation of rash, joint manifestations, thrombocytosis, and cardiac disease."</div>
                
                
                <div class="evidence-explanation">Thrombocytosis occurs during the subacute phase of KD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Cardiovascular
                    <span class="cat-count">4</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Conjunctivitis
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000509" target="_blank">
                                Conjunctivitis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000509)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Non-purulent (no pus)</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34814144" target="_blank">PMID:34814144</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In cross-sectional studies, KD was associated with allergic rhinitis (n = 6; OR, 1.69; 95% CI, 1.52-1.87), asthma (n = 3; OR, 1.72; 95% CI, 1.38-2.14), allergic conjunctivitis (n = 2; OR, 1.95; 95% CI, 1.68-2.27), and atopic dermatitis (n = 3; OR, 1.35; 95% CI, 1.22-1.49)."</div>
                
                
                <div class="evidence-explanation">The study shows that Kawasaki Disease is associated with allergic conjunctivitis, supporting the statement that conjunctivitis is very frequent in Kawasaki Disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32843441" target="_blank">PMID:32843441</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Both patients presented with fever lasting &gt;5 days and were found to have rash, conjunctival injection, and swollen lips."</div>
                
                
                <div class="evidence-explanation">The description of conjunctival injection in patients with Kawasaki Disease supports the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/7299613" target="_blank">PMID:7299613</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In a prospective series, ophthalmologic examinations on 10 children with Kawasaki disease showed that eight had anterior uveitis during the acute phase of the illness."</div>
                
                
                <div class="evidence-explanation">Although the study focuses on anterior uveitis, it indicates significant ocular involvement in Kawasaki Disease, supporting the statement indirectly.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Cervical Lymphadenopathy
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0025289" target="_blank">
                                Cervical lymphadenopathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0025289)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Often unilateral presentation</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Myocarditis
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0012819" target="_blank">
                                Myocarditis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0012819)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Aneurysm Formation
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002617" target="_blank">
                                Vascular dilatation
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002617)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31599798" target="_blank">PMID:31599798</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Kawasaki disease is a childhood vasculitis of unknown origin, whose major complication is the development of coronary artery aneurysms (CAA)."</div>
                
                
                <div class="evidence-explanation">This reference directly states that coronary artery aneurysm development is a major complication of Kawasaki disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21447126" target="_blank">PMID:21447126</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Histologically, coronary arteritis begins 6-8 days after the onset of KD, and leads immediately to inflammation of all layers of the artery. The inflammation spreads completely around the artery; as a result, structural components of the artery undergo intense damage; the artery then begins to dilate."</div>
                
                
                <div class="evidence-explanation">This reference describes the mechanism by which arterial inflammation leads to dilation and aneurysm formation in Kawasaki disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Immune
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Rash
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000988" target="_blank">
                                Skin rash
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000988)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26631821" target="_blank">PMID:26631821</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The main symptoms were fever (100%), exanthema (98%)..."</div>
                
                
                <div class="evidence-explanation">Exanthema, which refers to a widespread rash, was present in 98% of the adult patients with Kawasaki Disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/1440951" target="_blank">PMID:1440951</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We describe a four-year-old girl who presented with fever, a diffuse erythematous maculopapular rash..."</div>
                
                
                <div class="evidence-explanation">The case description includes a diffuse erythematous maculopapular rash as one of the clinical features.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33453126" target="_blank">PMID:33453126</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"All children with KD have fever accompanied by clinical signs, with four of the five classic criteria for complete KD being mucocutaneous..."</div>
                
                
                <div class="evidence-explanation">The abstract emphasizes the mucocutaneous manifestations, which include skin rashes, as critical for diagnosing Kawasaki Disease.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Metabolism
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Fever
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001945" target="_blank">
                                Fever
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001945)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30029859" target="_blank">PMID:30029859</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Fever, abdominal pain, and vomiting were the most frequent symptoms observed and typical Kawasaki disease signs and symptoms appeared after intestinal complaints in all cases."</div>
                
                
                <div class="evidence-explanation">The literature mentions fever as one of the most frequent symptoms observed in Kawasaki disease, supporting the statement that fever is a very frequent systemic diagnostic symptom of Kawasaki disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31900257" target="_blank">PMID:31900257</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The conundrum for acute paediatricians is which clinical features best distinguish the febrile child with possible KD, needing intravenous immunoglobulin, from the many other children with febrile illnesses."</div>
                
                
                <div class="evidence-explanation">The literature highlights the challenge of distinguishing Kawasaki disease from other febrile illnesses, indicating that fever is a very frequent systemic diagnostic symptom in Kawasaki disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26631821" target="_blank">PMID:26631821</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The main symptoms were fever (100%), exanthema (98%), changes in the extremities (91%), conjunctivitis (77%), oral cavity changes (89%), cervical adenitis (55%) and cardiac abnormalities (45%)."</div>
                
                
                <div class="evidence-explanation">The literature states that fever is present in 100% of the cases, supporting the statement that fever is a very frequent systemic diagnostic symptom of Kawasaki disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-5">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">4</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Swelling of Hands and Feet
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/1704148" target="_blank">PMID:1704148</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The six main clinical presentations of Kawasaki disease are: prolonged fever, conjunctivitis, lesions of the oral and pharyngeal mucosa, inflammatory reddening and swelling of the hands and feet, skin rash and cervical lymph node enlargement."</div>
                
                
                <div class="evidence-explanation">The literature explicitly mentions that swelling of the hands and feet is one of the six main clinical presentations of Kawasaki disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/3333141" target="_blank">PMID:3333141</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Early clinical features include fever, rash, conjunctival injection, dry reddened lips, oropharyngeal reddening, enlarged cervical nodes, and swelling and redness of hands and feet."</div>
                
                
                <div class="evidence-explanation">The literature lists swelling and redness of hands and feet as early clinical features of Kawasaki disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Peeling Skin
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Particularly on the fingers and toes, often during the subacute phase</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/6833960" target="_blank">PMID:6833960</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The second, subacute, phase begins with a decline of the acute findings and proceeds with desquamation of rash..."</div>
                
                
                <div class="evidence-explanation">The term &#39;desquamation&#39; refers to peeling of the skin, which supports the statement that peeling skin is a frequent dermatologic manifestation of Kawasaki Disease, particularly during the subacute phase.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/3333141" target="_blank">PMID:3333141</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Peeling of skin of fingers and toes, arthralgia, and marked thrombocytosis are frequent 1-2 weeks after onset."</div>
                
                
                <div class="evidence-explanation">This reference explicitly mentions that peeling of the skin on the fingers and toes is a frequent occurrence 1-2 weeks after the onset of Kawasaki Disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37065507" target="_blank">PMID:37065507</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Kawasaki disease&#39;s clinical manifestations range from oral skin disease to the blistering of the mucosa, symptoms involving the hands and the feet, skin disease of the palms and soles, a desquamative rash..."</div>
                
                
                <div class="evidence-explanation">The term &#39;desquamative rash&#39; indicates peeling skin, supporting the statement that this is a frequent dermatologic manifestation of Kawasaki Disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Red, Cracked Lips
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Includes &#34;strawberry tongue&#34; and inflammation in the mouth and throat</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15835487" target="_blank">PMID:15835487</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The disease can present with protean clinical manifestations which include high grade fever (for at least 5 days), rash, redness of the lips and a typical strawberry tongue, cervical lymph node enlargement (often unilateral), swelling over the hands/feet and, later a characteristic peripheral..."</div>
                
                
                <div class="evidence-explanation">The abstract mentions redness of the lips and a typical strawberry tongue as clinical manifestations of Kawasaki disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30903929" target="_blank">PMID:30903929</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Kawasaki disease (KD) is a febrile multisystemic vasculitis of unknown etiology whose coronary prognosis is improved by early diagnosis and management. ... ENT manifestations are frequently at the forefront of KD and constitute a misleading clinical picture responsible for delayed diagnosis and..."</div>
                
                
                <div class="evidence-explanation">The study indicates that ENT (ear, nose, and throat) manifestations, which include oropharyngeal symptoms, are frequently at the forefront of KD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/1440951" target="_blank">PMID:1440951</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We describe a four-year-old girl who presented with fever, a diffuse erythematous maculopapular rash, bilateral nonpurulent bulbar conjunctivitis, dry, red, fissured lips, a tongue with a strawberry &#39;appearance&#39;, an erythematous pharynx, indurative erythema, and edema and desquamation of the..."</div>
                
                
                <div class="evidence-explanation">The case description includes dry, red, fissured lips and a tongue with a strawberry &#39;appearance&#39;, supporting the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Coronary Artery Aneurysms
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Can lead to serious heart complications</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10512599" target="_blank">PMID:10512599</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Coronary artery aneurysms or ectasia develop in approximately 15-25% of children with the disease."</div>
                
                
                <div class="evidence-explanation">The literature indicates that coronary artery aneurysms are a common complication of Kawasaki disease, occurring in 15-25% of cases, which is more frequent than &#39;occasional&#39;.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31732547" target="_blank">PMID:31732547</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Twenty-three patients had SAAs, demonstrating an incidence of 14.2% (23 of 162) in patients who were screened at 1 month after onset. The proportion of patients with SAAs was estimated to be 2% (23 of 1148) of all patients with KD."</div>
                
                
                <div class="evidence-explanation">The incidence of coronary artery aneurysms (CAAs) in Kawasaki disease is significant, with a notable percentage of patients developing CAAs, indicating that the frequency is more than &#39;occasional&#39;.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34651205" target="_blank">PMID:34651205</a>
                    </span>
                    
                    <span class="evidence-support support-REFUTE">REFUTE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Among the 640 KD children, most were 1-5 years old (415/640, 64.8%). Children &lt; 1 year old (31.6%) and &gt; 5 years old (28.3%) were more likely to have cardiovascular complications."</div>
                
                
                <div class="evidence-explanation">The study shows a high incidence of cardiovascular complications in children with Kawasaki disease, indicating that coronary artery aneurysms and other heart complications are not just occasional.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">21</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    ITPKC
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk variant reduces negative regulation of Ca2+/NFAT signaling leading to enhanced T-cell activation)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    FCGR2A
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Mediates immune-complex driven neutrophil/monocyte activation)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    FCGR3A
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Mediates immune-complex driven neutrophil/monocyte activation)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    BLK
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(B lymphoid tyrosine kinase involved in B-cell receptor signaling)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    CD40
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Promotes B/T cell and endothelial activation via CD40-CD40L co-stimulation)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HLA-B
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(HLA associations support antigen-driven or superantigen-like T-cell responses)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    CASP3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Implicated in endothelial cell apoptosis and vascular remodeling during acute vasculitis)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    ORAI1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Store-operated calcium entry component; variants alter SOCE leading to dysregulated Ca2+ signaling)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    STIM1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Store-operated calcium entry component; variants alter SOCE leading to dysregulated Ca2+ signaling)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TGFBR2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(TGF-Œ≤ receptor involved in endothelial-to-mesenchymal transition)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    SMAD3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(TGF-Œ≤ signaling mediator involved in vascular remodeling)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TGFB2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(TGF-Œ≤ signaling involved in chronic vascular remodeling)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IL1B
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(IL-1Œ≤ promotes endothelial injury, inflammation and remodeling)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IL1R1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(IL-1 receptor; downstream of inflammasome activation)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TNF
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Induces endothelial cell expression of ICAM-1/VCAM-1, iNOS and proinflammatory cascade)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IL17A
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Th17 expansion and elevated IL-17 associate with coronary damage and IVIG resistance)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IL23A
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(IL-23 involved in Th17 axis and IL-17 signaling)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NLRP3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(NLRP3 inflammasome activation leads to IL-1Œ≤ release and pyroptosis)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NOS3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Reduced eNOS expression/activity leads to decreased NO, vasoconstriction, and thrombosis)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    ICAM1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Upregulated by TNF/IL-1 leading to leukocyte recruitment and endothelial dysfunction)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    VCAM1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Upregulated by TNF/IL-1 leading to vascular injury)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Intravenous Immunoglobulin (IVIG)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">First-line treatment to reduce inflammation and risk of coronary artery complications.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23283289" target="_blank">PMID:23283289</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Intravenous immunoglobulin (IVIG) and aspirin is the standard initial therapy in the treatment of Kawasaki disease."</div>
                
                
                <div class="evidence-explanation">The literature confirms that IVIG is part of the standard initial therapy for Kawasaki disease, aimed at reducing inflammation and preventing coronary artery complications.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38135926" target="_blank">PMID:38135926</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"For KD patients, male, children aged 3 to 9 years, and those with fever longer than 6 days before intravenous immunoglobulin (IVIG) use were more likely to have CAL."</div>
                
                
                <div class="evidence-explanation">The study discusses the use of IVIG and its timing in relation to the risk of coronary artery lesions, supporting its role in reducing such risks.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24034380" target="_blank">PMID:24034380</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The standard of care for treatment is intravenous immunoglobulin plus aspirin, but adding corticosteroids may provide additional benefit for high-risk patients."</div>
                
                
                <div class="evidence-explanation">The literature states that IVIG is the standard of care for treating Kawasaki disease to reduce coronary artery complications.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Aspirin
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000181" target="_blank">
                            MAXO:0000181
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Used in high doses for its anti-inflammatory and antipyretic effects, followed by a lower dose to prevent blood clots.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/9513217" target="_blank">PMID:9513217</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Treatment includes the hospitalization of the child and subsequent administration of high doses of aspirin and intravenous immunoglobulin. With recovery, aspirin doses are reduced and the child may be monitored at home with outpatient follow-up."</div>
                
                
                <div class="evidence-explanation">This reference confirms that high doses of aspirin are used initially for Kawasaki disease, followed by lower doses after recovery.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10935427" target="_blank">PMID:10935427</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Conventional therapy for KD includes intravenous gammaglobulin (2 g/kg as a single dose over 12 hours) and aspirin (acetylsalicylic acid; high dose until the fourteenth day of illness then low dose)."</div>
                
                
                <div class="evidence-explanation">This reference also supports the statement that high doses of aspirin are used initially, followed by lower doses.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32159800" target="_blank">PMID:32159800</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Low-dose aspirin plus IVIG might be as effective as high-dose aspirin plus IVIG for the initial treatment of Kawasaki disease. Considering that high-dose aspirin may cause more adverse reactions than low-dose aspirin, low-dose aspirin plus IVIG should be recommended as the first-line therapy in..."</div>
                
                
                <div class="evidence-explanation">This reference suggests that low-dose aspirin might be equally effective as high-dose aspirin and should be recommended to avoid adverse reactions, indicating a shift in treatment preference.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Anakinra
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">IL-1 receptor antagonist used for IVIG-resistant Kawasaki disease to block IL-1-mediated endothelial injury.</div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Cyclosporine
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Calcineurin inhibitor used to modulate Ca2+/NFAT signaling in genetically susceptible patients.</div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Corticosteroids
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Used in cases resistant to IVIG or with severe inflammation.</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31914832" target="_blank">PMID:31914832</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We suggest using methylprednisolone pulse therapy as an alternative rescue therapy for immunoglobulin-resistant KD, as well as identifying high-risk patients who need initial corticosteroid with IVIG treatment with an adequate route, dose, and duration."</div>
                
                
                <div class="evidence-explanation">The literature supports the use of corticosteroids in cases of Kawasaki Disease that are resistant to IVIG or in high-risk patients with severe inflammation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29101553" target="_blank">PMID:29101553</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"&#34;Resistant&#34; Kawasaki disease is defined by the American Heart Association as failure to respond within 36 h following the first dose of intravenous immunoglobulin. The optimal management of resistant Kawasaki disease remains uncertain, the outcomes are potentially serious, and the cost of some..."</div>
                
                
                <div class="evidence-explanation">This reference discusses the management of resistant Kawasaki Disease, which includes considering corticosteroid use.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33541111" target="_blank">PMID:33541111</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"To prevent CAA, more intensified or adjunctive therapies using other agents, such as pulsed methylprednisolone, ciclosporin, infliximab, and Anakinra, should be considered for patients with these risk factors."</div>
                
                
                <div class="evidence-explanation">This reference mentions the use of pulsed methylprednisolone (a corticosteroid) for patients with Kawasaki Disease who are at risk of developing coronary artery abnormalities, indicating severe inflammation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    C-Reactive Protein (CRP)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Indicator of inflammation</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34078404" target="_blank">PMID:34078404</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"CAL were found in 12.9 and 18.3% of the high and low CRP patients, respectively (p &lt; 0.001), based on z-scores; and in 9.9 and 12.5%, respectively (p = 0.001), based on the Japanese criteria in the acute phase."</div>
                
                
                <div class="evidence-explanation">The study indicates that CRP levels are elevated in Kawasaki Disease patients, with specific percentages of high and low CRP levels noted.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39117827" target="_blank">PMID:39117827</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Kawasaki disease (KD) is a hyperinflammatory syndrome manifesting as an acute systemic vasculitis characterized by fever, nonsuppurative conjunctival injection, rash, oral mucositis, extremity changes, and cervical lymphadenopathy."</div>
                
                
                <div class="evidence-explanation">The abstract describes KD as a hyperinflammatory syndrome, implying elevated inflammatory markers such as CRP.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37551875" target="_blank">PMID:37551875</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Complete blood count, C-reactive protein (CRP), liver and renal function tests, serum electrolytes, chest X-ray, NT-proBNP level, Bactec blood culture, urine microscopy and culture along with detailed physical examination was done for all cases and control."</div>
                
                
                <div class="evidence-explanation">The study includes CRP as part of the diagnostic tests for Kawasaki Disease, indicating its relevance as an inflammatory marker.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Erythrocyte Sedimentation Rate (ESR)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Indicator of inflammation</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36604937" target="_blank">PMID:36604937</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"NLR &gt;/=2.08 was 82% sensitive and 80% specific in predicting CAL. ESR &gt;/=88 mm/h was 85% sensitive and 64% specific in predicting IVIg resistance."</div>
                
                
                <div class="evidence-explanation">The study indicates that ESR is elevated in Kawasaki Disease and can be used to predict IVIg resistance.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33413220" target="_blank">PMID:33413220</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In comparison between KDSS and TSS, patients with KDSS had a significantly higher erythrocyte sedimentation rate (ESR) and significantly lower creatinine."</div>
                
                
                <div class="evidence-explanation">The study shows that patients with Kawasaki Disease Shock Syndrome (KDSS) have significantly higher ESR levels.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15677370" target="_blank">PMID:15677370</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The erythrocyte sedimentation rate (ESR) increased significantly 24 h after IVIG, and the elevated level was sustained for 7 days."</div>
                
                
                <div class="evidence-explanation">This reference shows that ESR levels are elevated during the acute stage of Kawasaki Disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Platelet Count
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Often seen in the subacute phase</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33527178" target="_blank">PMID:33527178</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In Kawasaki disease (KD), thrombocytosis is commonly found in the subacute phase."</div>
                
                
                <div class="evidence-explanation">The abstract states that thrombocytosis (elevated platelet count) is commonly found in the subacute phase of Kawasaki disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/6833960" target="_blank">PMID:6833960</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The second, subacute, phase begins with a decline of the acute findings and proceeds with desquamation of rash, joint manifestations, thrombocytosis, and cardiac disease."</div>
                
                
                <div class="evidence-explanation">The text explicitly mentions that thrombocytosis occurs during the subacute phase of Kawasaki disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Kawasaki Disease
creation_date: &#39;2025-12-04T16:57:31Z&#39;
updated_date: &#39;2026-02-17T21:53:14Z&#39;
description: Kawasaki Disease is a condition in children that involves
  inflammation of blood vessels throughout the body and is characterized by
  fever, rash, and other symptoms.
category: Pediatric Condition
parents:
- Vasculitis
prevalence:
- population: Children under 5
  percentage: Rare
  evidence:
  - reference: PMID:10392592
    supports: REFUTE
    snippet: Most children who contract this illness are less than two years
      old, and 80 percent of affected children are younger than five years of
      age.
    explanation: The statement that Kawasaki disease is rare in children under 5
      is refuted by the literature, which indicates that 80% of affected
      children are younger than five years of age.
  - reference: PMID:36611091
    supports: REFUTE
    snippet: 83% of patients were &lt; 5 years of age and 10% were &lt; 6 months.
    explanation: The study shows that a significant proportion of Kawasaki
      disease cases occur in children under 5 years of age, refuting the
      statement that it is rare in this population.
progression:
- phase: Onset
  age_range: 6 months to 5 years
  notes: Sudden onset with high fever
  evidence:
  - reference: PMID:36472296
    supports: PARTIAL
    snippet: Given the variety and inconsistency of the clinical symptoms (the
      child had four of the five mandatory criteria together with prolonged
      fever), there was a late diagnosis, namely on day 10 of the disease.
    explanation: This reference mentions prolonged fever as a symptom of
      Kawasaki Disease but does not specify the sudden onset of high fever.
  - reference: PMID:34459958
    supports: PARTIAL
    snippet: A retrospective study that compared children younger than 6 months
      versus older children of a Spanish cohort of patients diagnosed with
      Kawasaki disease between 2011 and 2016 (Kawa-Race study).
    explanation: This reference provides information on Kawasaki Disease in
      children younger than 6 months and older but does not specifically mention
      the age range of 6 months to 5 years or the sudden onset with high fever.
  - reference: PMID:37553209
    supports: PARTIAL
    snippet: The mean age was 39.8 months (SD 37) and 592 (59%) were boys.
    explanation: This reference indicates that the mean age of Kawasaki Disease
      patients was within the 6 months to 5 years range but does not
      specifically mention the sudden onset with high fever.
  - reference: PMID:31910632
    supports: PARTIAL
    snippet: Kawasaki disease (KD) is the most frequent cause of coronary artery
      aneurysm (CAA) in children.
    explanation: This reference focuses on coronary artery aneurysm in children
      with Kawasaki Disease but does not provide specific details about the age
      range or the sudden onset with high fever.
  - reference: PMID:36611091
    supports: PARTIAL
    snippet: 83% of patients were &lt; 5 years of age and 10% were &lt; 6 months.
    explanation: This reference mentions that 83% of Kawasaki Disease patients
      were under 5 years of age but does not specify the sudden onset with high
      fever.
- phase: Acute
  duration: 1-2 weeks
  notes: High fever, rash, conjunctivitis, swollen hands and feet
  evidence:
  - reference: PMID:9665974
    supports: PARTIAL
    snippet: The illness is manifested by prolonged fever, conjunctival
      injection, enanthem, exanthem, erythema and swelling of the hands and
      feet, and cervical adenopathy. These acute features of illness are
      self-limiting.
    explanation: The reference confirms the symptoms mentioned in the statement
      (high fever, rash, conjunctivitis, swollen hands and feet) during the
      acute phase of Kawasaki Disease. However, it does not specify the exact
      duration of 1-2 weeks.
  - reference: PMID:31974671
    supports: PARTIAL
    snippet: Arthritis in KD is usually non-erosive, self-limiting, and responds
      well to a short course of NSAIDs.
    explanation: The reference mentions that arthritis in KD is self-limiting,
      which implies a limited duration. However, it does not explicitly confirm
      the 1-2 week duration for the acute phase.
  - reference: PMID:39117827
    supports: PARTIAL
    snippet: Kawasaki disease (KD) is a hyperinflammatory syndrome manifesting
      as an acute systemic vasculitis characterized by fever, nonsuppurative
      conjunctival injection, rash, oral mucositis, extremity changes, and
      cervical lymphadenopathy.
    explanation: The reference confirms the symptoms mentioned in the statement
      during the acute phase of Kawasaki Disease. However, it does not specify
      the exact duration of 1-2 weeks.
- phase: Subacute
  duration: 2-4 weeks
  notes: Peeling skin, joint pain, possible coronary artery changes
  evidence:
  - reference: PMID:28580712
    supports: PARTIAL
    snippet: Kawasaki disease begins as a necrotizing arteritis with
      neutrophilic infiltrate, followed by subacute/chronic changes and luminal
      myofibroblastic proliferation that can cause coronary artery stenosis.
    explanation: This reference mentions the subacute phase and coronary artery
      changes but does not specify the duration of 2-4 weeks or mention peeling
      skin and joint pain.
  - reference: PMID:33453126
    supports: PARTIAL
    snippet: All children with KD have fever accompanied by clinical signs, with
      four of the five classic criteria for complete KD being mucocutaneous,
      thus creating an important role for dermatologists.
    explanation: This reference discusses skin manifestations, which could
      include peeling, but does not specify the subacute phase duration or joint
      pain.
- phase: Convalescent
  duration: 6-8 weeks
  notes: Symptoms resolve, but coronary artery abnormalities may persist
  evidence:
  - reference: PMID:28580712
    supports: PARTIAL
    snippet: Kawasaki disease is an acute febrile arteritis of childhood that
      can result in coronary artery aneurysms if untreated in the first 10 and
      ideally 7 days of illness. Kawasaki disease begins as a necrotizing
      arteritis with neutrophilic infiltrate, followed by subacute/chronic
      changes and luminal myofibroblastic proliferation that can cause coronary
      artery stenosis.
    explanation: The literature indicates that Kawasaki disease can lead to
      coronary artery abnormalities, but it does not specify that the
      convalescent phase lasts 6-8 weeks. It supports the persistence of
      coronary artery abnormalities but does not confirm the exact duration of
      the convalescent phase.
  - reference: PMID:17033807
    supports: PARTIAL
    snippet: Conclusively, the most important predictor of CAA in KD is total
      duration of fever longer than 8 days. Early identification of IVGG
      non-responders and active therapeutic intervention for fever in KD cases
      might decrease the incidence of CAA.
    explanation: This reference discusses the importance of early intervention
      to prevent coronary artery abnormalities but does not provide specific
      information about the duration of the convalescent phase.
  - reference: PMID:29437127
    supports: NO_EVIDENCE
    snippet: Kawasaki Disease.
    explanation: This reference does not provide specific information about the
      duration of the convalescent phase or the persistence of coronary artery
      abnormalities.
pathophysiology:
- name: Vascular Inflammation
  description: Widespread inflammation of medium-sized arteries, including
    coronary arteries.
  cell_types:
  - preferred_term: vascular endothelial cell
    description: Primary target cells undergoing activation and dysfunction
    term:
      id: CL:0000071
      label: blood vessel endothelial cell
  - preferred_term: neutrophil
    description: Recruited to vessel walls during necrotizing arteritis phase
    term:
      id: CL:0000775
      label: neutrophil
  - preferred_term: monocyte
    description: Activated by immune complexes and FcŒ≥R signaling
    term:
      id: CL:0000576
      label: monocyte
  - preferred_term: macrophage
    description: Present in coronary lesions producing cytokines
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: endothelial cell activation
    description: Cytokine-driven upregulation of adhesion molecules and
      inflammatory mediators
    term:
      id: GO:0042118
      label: endothelial cell activation
  - preferred_term: leukocyte adhesion to vascular endothelial cell
    description: ICAM-1/VCAM-1 mediated leukocyte recruitment
    term:
      id: GO:1904996
      label: positive regulation of leukocyte adhesion to vascular endothelial
        cell
  - preferred_term: inflammatory response
    description: Systemic hyperinflammatory syndrome with cytokine cascades
    term:
      id: GO:0006954
      label: inflammatory response
  locations:
  - preferred_term: coronary artery
    description: Primary site of arteritis and aneurysm formation
    term:
      id: UBERON:0001621
      label: coronary artery
  - preferred_term: artery wall
    description: All three layers (intima, media, adventitia) undergo
      inflammation
    term:
      id: UBERON:0035965
      label: artery wall
  downstream:
  - target: Aneurysm Formation
    description: Coronary arteritis causes structural damage to arterial walls
      leading to dilation and aneurysm formation.
    evidence:
    - reference: PMID:21447126
      supports: SUPPORT
      snippet: Histologically, coronary arteritis begins 6-8 days after the
        onset of KD, and leads immediately to inflammation of all layers of the
        artery. The inflammation spreads completely around the artery; as a
        result, structural components of the artery undergo intense damage; the
        artery then begins to dilate.
      explanation: This reference directly establishes the mechanistic link
        between coronary arteritis and aneurysm formation through structural
        damage.
  evidence:
  - reference: PMID:23188196
    supports: SUPPORT
    snippet: Kawasaki disease (KD) is considered to be a kind of systemic
      vasculitis syndrome. It most frequently affects infants and young children
      and primarily invades medium-sized muscular arteries, including the
      coronary arteries.
    explanation: The literature confirms that Kawasaki disease involves
      widespread inflammation of medium-sized arteries, including coronary
      arteries.
  - reference: PMID:31599798
    supports: SUPPORT
    snippet: Kawasaki disease is a childhood vasculitis of unknown origin, whose
      major complication is the development of coronary artery aneurysms (CAA).
    explanation: The literature supports that Kawasaki disease leads to vascular
      inflammation and aneurysm formation.
  - reference: PMID:27090101
    supports: SUPPORT
    snippet: Coronary angiography showed multiple aneurysms which suggested
      sequelae of misdiagnosed Kawasaki disease.
    explanation: The case report indicates that Kawasaki disease can lead to
      aneurysm formation as a result of vascular inflammation.
  - reference: PMID:36102118
    supports: SUPPORT
    snippet: Long-term physiological dysfunction in coronary/systemic
      vasculature may persist in individuals with Kawasaki disease even in the
      absence of coronary artery abnormalities.
    explanation: The literature suggests long-term vascular dysfunction due to
      Kawasaki disease, supporting the idea of widespread vascular inflammation.
  - reference: PMID:35420684
    supports: SUPPORT
    snippet: Kawasaki disease, an acute febrile illness, can cause vasculitis in
      the coronary arteries.
    explanation: The literature confirms that Kawasaki disease causes
      inflammation in coronary arteries, leading to complications such as
      aneurysms.
  - reference: PMID:16990356
    supports: SUPPORT
    snippet: Kawasaki disease is an acute inflammatory syndrome that takes the
      form of systemic vasculitis, and predominantly affects children. Important
      complications of this disease are coronary artery dilation and aneurysm
      formation.
    explanation: The literature supports the statement that Kawasaki disease
      involves widespread vascular inflammation and aneurysm formation.
- name: Immune Response Dysregulation
  description: An abnormal immune response leading to vessel wall damage and
    inflammation.
  cell_types:
  - preferred_term: CD8-positive, alpha-beta T cell
    description: CD8+ T cells present in coronary lesions
    term:
      id: CL:0000625
      label: CD8-positive, alpha-beta T cell
  - preferred_term: T-helper 17 cell
    description: Th17 expansion associated with coronary damage and IVIG
      resistance
    term:
      id: CL:0000899
      label: T-helper 17 cell
  - preferred_term: regulatory T cell
    description: Treg imbalance contributes to immune dysregulation
    term:
      id: CL:0000815
      label: regulatory T cell
  - preferred_term: plasmablast
    description: Convergent antigen-driven plasmablast responses in some
      patients
    term:
      id: CL:0000980
      label: plasmablast
  - preferred_term: plasma cell
    description: IgA plasma cells found in coronary lesions
    term:
      id: CL:0000786
      label: plasma cell
  - preferred_term: dendritic cell
    description: Involved in antigen presentation and T-cell activation
    term:
      id: CL:0000451
      label: dendritic cell
  biological_processes:
  - preferred_term: NLRP3 inflammasome complex assembly
    description: NLRP3 inflammasome activation leading to IL-1Œ≤ release
    term:
      id: GO:0072559
      label: NLRP3 inflammasome complex assembly
  - preferred_term: interleukin-1 beta production
    description: IL-1Œ≤ promotes endothelial injury and inflammation
    term:
      id: GO:0032611
      label: interleukin-1 beta production
  - preferred_term: tumor necrosis factor production
    description: TNF-Œ± induces endothelial activation and NF-Œ∫B signaling
    term:
      id: GO:0032640
      label: tumor necrosis factor production
  - preferred_term: interleukin-17 production
    description: IL-17 from Th17 cells promotes neutrophil recruitment
    term:
      id: GO:0032620
      label: interleukin-17 production
  - preferred_term: calcium ion transmembrane transport
    description: Dysregulated Ca2+/calcineurin-NFAT signaling pathway
    term:
      id: GO:0070588
      label: calcium ion transmembrane transport
  - preferred_term: T cell activation
    description: Enhanced T-cell activation via CD40-CD40L co-stimulation
    term:
      id: GO:0042110
      label: T cell activation
  - preferred_term: complement activation
    description: Complement fixation contributes to vascular injury
    term:
      id: GO:0006956
      label: complement activation
  evidence:
  - reference: PMID:34890998
    supports: SUPPORT
    snippet: Increasing evidence shows that the pathogenesis of Kawasaki disease
      (KD) is caused by abnormal and unbalanced innate and adaptive immune
      responses.
    explanation: The literature supports the statement that Kawasaki Disease is
      characterized by immune response dysregulation leading to vessel wall
      damage and inflammation.
  - reference: PMID:30183655
    supports: SUPPORT
    snippet: Kawasaki disease (KD) is a vasculitis that is part of systemic
      vasculitis syndrome. It affects medium-sized vessels and is characterized
      by hypercytokinemia.
    explanation: This reference supports that KD involves immune dysregulation
      leading to vessel wall damage.
  - reference: PMID:30619331
    supports: SUPPORT
    snippet: Others have favored an autoreactive hypothesis that KD is triggered
      by an antigen that shares homology with structures in the vascular wall,
      and molecular mimicry resulting in an immune response directed to that
      tissue.
    explanation: This supports the notion of an abnormal immune response leading
      to vessel wall damage in KD.
  - reference: PMID:39117827
    supports: SUPPORT
    snippet: Kawasaki disease (KD) is a hyperinflammatory syndrome manifesting
      as an acute systemic vasculitis characterized by fever, nonsuppurative
      conjunctival injection, rash, oral mucositis, extremity changes, and
      cervical lymphadenopathy.
    explanation: This reference supports the statement by describing KD as a
      hyperinflammatory syndrome, which involves immune dysregulation.
phenotypes:
- category: Systemic
  name: Fever
  description: High fever lasting at least 5 days, a mandatory criterion for
    diagnosis of Kawasaki disease.
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:30029859
    supports: SUPPORT
    snippet: Fever, abdominal pain, and vomiting were the most frequent symptoms
      observed and typical Kawasaki disease signs and symptoms appeared after
      intestinal complaints in all cases.
    explanation: The literature mentions fever as one of the most frequent
      symptoms observed in Kawasaki disease, supporting the statement that fever
      is a very frequent systemic diagnostic symptom of Kawasaki disease.
  - reference: PMID:31900257
    supports: SUPPORT
    snippet: The conundrum for acute paediatricians is which clinical features
      best distinguish the febrile child with possible KD, needing intravenous
      immunoglobulin, from the many other children with febrile illnesses.
    explanation: The literature highlights the challenge of distinguishing
      Kawasaki disease from other febrile illnesses, indicating that fever is a
      very frequent systemic diagnostic symptom in Kawasaki disease.
  - reference: PMID:26631821
    supports: SUPPORT
    snippet: The main symptoms were fever (100%), exanthema (98%), changes in
      the extremities (91%), conjunctivitis (77%), oral cavity changes (89%),
      cervical adenitis (55%) and cardiac abnormalities (45%).
    explanation: The literature states that fever is present in 100% of the
      cases, supporting the statement that fever is a very frequent systemic
      diagnostic symptom of Kawasaki disease.
  phenotype_term:
    preferred_term: Fever
    description: Elevated body temperature above the normal range, typically
      above 38¬∞C (100.4¬∞F).
    term:
      id: HP:0001945
      label: Fever
- category: Dermatologic
  name: Rash
  description: Polymorphous exanthem typically affecting the trunk and
    extremities, without vesicles or crusting.
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:26631821
    supports: SUPPORT
    snippet: The main symptoms were fever (100%), exanthema (98%)...
    explanation: Exanthema, which refers to a widespread rash, was present in
      98% of the adult patients with Kawasaki Disease.
  - reference: PMID:1440951
    supports: SUPPORT
    snippet: We describe a four-year-old girl who presented with fever, a
      diffuse erythematous maculopapular rash...
    explanation: The case description includes a diffuse erythematous
      maculopapular rash as one of the clinical features.
  - reference: PMID:33453126
    supports: SUPPORT
    snippet: All children with KD have fever accompanied by clinical signs, with
      four of the five classic criteria for complete KD being mucocutaneous...
    explanation: The abstract emphasizes the mucocutaneous manifestations, which
      include skin rashes, as critical for diagnosing Kawasaki Disease.
  - reference: PMID:23481152
    supports: SUPPORT
    snippet: This is a report of a 4-year-old Hispanic boy who presented with
      skin changes to the lips and oral cavity, a generalized rash...
    explanation: The case report mentions a generalized rash as one of the
      symptoms of Kawasaki Disease.
  - reference: PMID:32843441
    supports: SUPPORT
    snippet: Both patients presented with fever lasting &gt;5 days and were found
      to have rash, conjunctival injection, and swollen lips.
    explanation: The patients with COVID-19 inflammatory syndrome had clinical
      features resembling Kawasaki Disease, including a rash.
  phenotype_term:
    preferred_term: Skin rash
    description: Visible change in skin color or texture, typically involving
      erythema or papules.
    term:
      id: HP:0000988
      label: Skin rash
- category: Ocular
  name: Conjunctivitis
  description: Bilateral bulbar conjunctival injection without exudate,
    typically limbal sparing.
  frequency: VERY_FREQUENT
  notes: Non-purulent (no pus)
  evidence:
  - reference: PMID:34814144
    supports: SUPPORT
    snippet: In cross-sectional studies, KD was associated with allergic
      rhinitis (n = 6; OR, 1.69; 95% CI, 1.52-1.87), asthma (n = 3; OR, 1.72;
      95% CI, 1.38-2.14), allergic conjunctivitis (n = 2; OR, 1.95; 95% CI,
      1.68-2.27), and atopic dermatitis (n = 3; OR, 1.35; 95% CI, 1.22-1.49).
    explanation: The study shows that Kawasaki Disease is associated with
      allergic conjunctivitis, supporting the statement that conjunctivitis is
      very frequent in Kawasaki Disease.
  - reference: PMID:32843441
    supports: SUPPORT
    snippet: Both patients presented with fever lasting &gt;5 days and were found
      to have rash, conjunctival injection, and swollen lips.
    explanation: The description of conjunctival injection in patients with
      Kawasaki Disease supports the statement.
  - reference: PMID:7299613
    supports: SUPPORT
    snippet: In a prospective series, ophthalmologic examinations on 10 children
      with Kawasaki disease showed that eight had anterior uveitis during the
      acute phase of the illness.
    explanation: Although the study focuses on anterior uveitis, it indicates
      significant ocular involvement in Kawasaki Disease, supporting the
      statement indirectly.
  phenotype_term:
    preferred_term: Conjunctivitis
    description: Inflammation of the conjunctiva resulting in redness and
      irritation of the eye.
    term:
      id: HP:0000509
      label: Conjunctivitis
- category: Musculoskeletal
  name: Swelling of Hands and Feet
  description: Acute erythema and induration of the hands and feet with
    subsequent periungual desquamation.
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:1704148
    supports: SUPPORT
    snippet: &#39;The six main clinical presentations of Kawasaki disease are: prolonged
      fever, conjunctivitis, lesions of the oral and pharyngeal mucosa, inflammatory
      reddening and swelling of the hands and feet, skin rash and cervical lymph node
      enlargement.&#39;
    explanation: The literature explicitly mentions that swelling of the hands
      and feet is one of the six main clinical presentations of Kawasaki
      disease.
  - reference: PMID:3333141
    supports: SUPPORT
    snippet: Early clinical features include fever, rash, conjunctival
      injection, dry reddened lips, oropharyngeal reddening, enlarged cervical
      nodes, and swelling and redness of hands and feet.
    explanation: The literature lists swelling and redness of hands and feet as
      early clinical features of Kawasaki disease.
- category: Dermatologic
  frequency: FREQUENT
  name: Peeling Skin
  description: Desquamation beginning at the tips of fingers and toes, spreading
    to palms and soles during recovery phase.
  notes: Particularly on the fingers and toes, often during the subacute phase
  evidence:
  - reference: PMID:6833960
    supports: SUPPORT
    snippet: The second, subacute, phase begins with a decline of the acute
      findings and proceeds with desquamation of rash...
    explanation: The term &#39;desquamation&#39; refers to peeling of the skin, which
      supports the statement that peeling skin is a frequent dermatologic
      manifestation of Kawasaki Disease, particularly during the subacute phase.
  - reference: PMID:3333141
    supports: SUPPORT
    snippet: Peeling of skin of fingers and toes, arthralgia, and marked
      thrombocytosis are frequent 1-2 weeks after onset.
    explanation: This reference explicitly mentions that peeling of the skin on
      the fingers and toes is a frequent occurrence 1-2 weeks after the onset of
      Kawasaki Disease.
  - reference: PMID:37065507
    supports: SUPPORT
    snippet: Kawasaki disease&#39;s clinical manifestations range from oral skin
      disease to the blistering of the mucosa, symptoms involving the hands and
      the feet, skin disease of the palms and soles, a desquamative rash...
    explanation: The term &#39;desquamative rash&#39; indicates peeling skin, supporting
      the statement that this is a frequent dermatologic manifestation of
      Kawasaki Disease.
- category: Oropharyngeal
  frequency: VERY_FREQUENT
  name: Red, Cracked Lips
  description: Erythema, dryness, and fissuring of the lips with strawberry
    tongue and diffuse oropharyngeal erythema.
  notes: Includes &#34;strawberry tongue&#34; and inflammation in the mouth and throat
  evidence:
  - reference: PMID:15835487
    supports: SUPPORT
    snippet: The disease can present with protean clinical manifestations which
      include high grade fever (for at least 5 days), rash, redness of the lips
      and a typical strawberry tongue, cervical lymph node enlargement (often
      unilateral), swelling over the hands/feet and, later a characteristic
      peripheral desquamation over the fingers and toes.
    explanation: The abstract mentions redness of the lips and a typical
      strawberry tongue as clinical manifestations of Kawasaki disease.
  - reference: PMID:30903929
    supports: SUPPORT
    snippet: Kawasaki disease (KD) is a febrile multisystemic vasculitis of
      unknown etiology whose coronary prognosis is improved by early diagnosis
      and management. ... ENT manifestations are frequently at the forefront of
      KD and constitute a misleading clinical picture responsible for delayed
      diagnosis and potentially inappropriate medico-surgical management.
    explanation: The study indicates that ENT (ear, nose, and throat)
      manifestations, which include oropharyngeal symptoms, are frequently at
      the forefront of KD.
  - reference: PMID:1440951
    supports: SUPPORT
    snippet: We describe a four-year-old girl who presented with fever, a
      diffuse erythematous maculopapular rash, bilateral nonpurulent bulbar
      conjunctivitis, dry, red, fissured lips, a tongue with a strawberry
      &#39;appearance&#39;, an erythematous pharynx, indurative erythema, and edema and
      desquamation of the face, hands and feet.
    explanation: The case description includes dry, red, fissured lips and a
      tongue with a strawberry &#39;appearance&#39;, supporting the statement.
  - reference: PMID:23481152
    supports: SUPPORT
    snippet: This is a report of a 4-year-old Hispanic boy who presented with
      skin changes to the lips and oral cavity, a generalized rash, edema of
      hands and feet, and peeling of the periungual areas of the fingers as well
      as to the groin and perianal areas.
    explanation: The report includes skin changes to the lips and oral cavity,
      which supports the statement.
- category: Cardiovascular
  frequency: OCCASIONAL
  name: Coronary Artery Aneurysms
  description: Abnormal dilation of coronary arteries that can lead to
    thrombosis, stenosis, and myocardial infarction.
  notes: Can lead to serious heart complications
  evidence:
  - reference: PMID:10512599
    supports: REFUTE
    snippet: Coronary artery aneurysms or ectasia develop in approximately
      15-25% of children with the disease.
    explanation: The literature indicates that coronary artery aneurysms are a
      common complication of Kawasaki disease, occurring in 15-25% of cases,
      which is more frequent than &#39;occasional&#39;.
  - reference: PMID:31732547
    supports: REFUTE
    snippet: Twenty-three patients had SAAs, demonstrating an incidence of 14.2%
      (23 of 162) in patients who were screened at 1 month after onset. The
      proportion of patients with SAAs was estimated to be 2% (23 of 1148) of
      all patients with KD.
    explanation: The incidence of coronary artery aneurysms (CAAs) in Kawasaki
      disease is significant, with a notable percentage of patients developing
      CAAs, indicating that the frequency is more than &#39;occasional&#39;.
  - reference: PMID:34651205
    supports: REFUTE
    snippet: Among the 640 KD children, most were 1-5 years old (415/640,
      64.8%). Children &lt; 1 year old (31.6%) and &gt; 5 years old (28.3%) were more
      likely to have cardiovascular complications.
    explanation: The study shows a high incidence of cardiovascular
      complications in children with Kawasaki disease, indicating that coronary
      artery aneurysms and other heart complications are not just occasional.
  - reference: PMID:23075819
    supports: REFUTE
    snippet: Patients with persistent or remodeled coronary aneurysms after
      Kawasaki disease have a high rate of complications including thrombosis or
      stenosis leading to myocardial infarction.
    explanation: The literature indicates a high rate of complications from
      coronary artery aneurysms in Kawasaki disease, suggesting that these
      complications are not occasional but rather significant.
- category: Hematologic
  name: Thrombocytosis
  description: Elevated platelet count commonly found in the subacute phase of
    Kawasaki disease.
  frequency: VERY_FREQUENT
  notes: Often appears 1-2 weeks after onset
  evidence:
  - reference: PMID:33527178
    supports: SUPPORT
    snippet: In Kawasaki disease (KD), thrombocytosis is commonly found in the
      subacute phase.
    explanation: Thrombocytosis is a common finding during the subacute phase of
      KD.
  - reference: PMID:6833960
    supports: SUPPORT
    snippet: The second, subacute, phase begins with a decline of the acute
      findings and proceeds with desquamation of rash, joint manifestations,
      thrombocytosis, and cardiac disease.
    explanation: Thrombocytosis occurs during the subacute phase of KD.
  phenotype_term:
    preferred_term: Thrombocytosis
    description: Abnormally increased platelet count in the blood.
    term:
      id: HP:0001894
      label: Thrombocytosis
- category: Lymphatic
  name: Cervical Lymphadenopathy
  description: Enlarged cervical lymph nodes, often unilateral, one of the
    classic diagnostic criteria for Kawasaki disease.
  frequency: FREQUENT
  notes: Often unilateral presentation
  phenotype_term:
    preferred_term: Cervical lymphadenopathy
    description: Enlargement of lymph nodes in the neck region.
    term:
      id: HP:0025289
      label: Cervical lymphadenopathy
- category: Cardiovascular
  name: Myocarditis
  description: Inflammation of the myocardium that can occur during the acute
    phase of Kawasaki disease.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Myocarditis
    description: Inflammation of the cardiac muscle.
    term:
      id: HP:0012819
      label: Myocarditis
- category: Cardiovascular
  name: Aneurysm Formation
  description: Vascular dilation resulting from inflammatory weakening of vessel
    walls, affecting coronary and other medium-sized arteries.
  frequency: FREQUENT
  evidence:
  - reference: PMID:31599798
    supports: SUPPORT
    snippet: Kawasaki disease is a childhood vasculitis of unknown origin, whose
      major complication is the development of coronary artery aneurysms (CAA).
    explanation: This reference directly states that coronary artery aneurysm
      development is a major complication of Kawasaki disease.
  - reference: PMID:21447126
    supports: SUPPORT
    snippet: Histologically, coronary arteritis begins 6-8 days after the onset
      of KD, and leads immediately to inflammation of all layers of the artery.
      The inflammation spreads completely around the artery; as a result,
      structural components of the artery undergo intense damage; the artery
      then begins to dilate.
    explanation: This reference describes the mechanism by which arterial
      inflammation leads to dilation and aneurysm formation in Kawasaki disease.
  phenotype_term:
    preferred_term: Aneurysm Formation
    description: Abnormal focal dilation of a blood vessel due to weakening of
      the vessel wall.
    term:
      id: HP:0002617
      label: Vascular dilatation
biochemical:
- name: C-Reactive Protein (CRP)
  presence: Elevated
  context: Indicator of inflammation
  evidence:
  - reference: PMID:34078404
    supports: SUPPORT
    snippet: CAL were found in 12.9 and 18.3% of the high and low CRP patients,
      respectively (p &lt; 0.001), based on z-scores; and in 9.9 and 12.5%,
      respectively (p = 0.001), based on the Japanese criteria in the acute
      phase.
    explanation: The study indicates that CRP levels are elevated in Kawasaki
      Disease patients, with specific percentages of high and low CRP levels
      noted.
  - reference: PMID:39117827
    supports: SUPPORT
    snippet: Kawasaki disease (KD) is a hyperinflammatory syndrome manifesting
      as an acute systemic vasculitis characterized by fever, nonsuppurative
      conjunctival injection, rash, oral mucositis, extremity changes, and
      cervical lymphadenopathy.
    explanation: The abstract describes KD as a hyperinflammatory syndrome,
      implying elevated inflammatory markers such as CRP.
  - reference: PMID:37551875
    supports: SUPPORT
    snippet: Complete blood count, C-reactive protein (CRP), liver and renal
      function tests, serum electrolytes, chest X-ray, NT-proBNP level, Bactec
      blood culture, urine microscopy and culture along with detailed physical
      examination was done for all cases and control.
    explanation: The study includes CRP as part of the diagnostic tests for
      Kawasaki Disease, indicating its relevance as an inflammatory marker.
  - reference: PMID:34731266
    supports: SUPPORT
    snippet: The KD group had a significantly higher level of initial c-reactive
      protein (CRP) compared to the BI and NBI groups, with a cutoff value of
      4.85 mg/dL in comparison with the BI group and 3.32 mg/dL in comparison
      with the NBI group.
    explanation: The study provides specific CRP levels that are elevated in
      Kawasaki Disease compared to bacterial and non-bacterial infections.
- name: Erythrocyte Sedimentation Rate (ESR)
  presence: Elevated
  context: Indicator of inflammation
  evidence:
  - reference: PMID:36604937
    supports: SUPPORT
    snippet: NLR &gt;/=2.08 was 82% sensitive and 80% specific in predicting CAL.
      ESR &gt;/=88 mm/h was 85% sensitive and 64% specific in predicting IVIg
      resistance.
    explanation: The study indicates that ESR is elevated in Kawasaki Disease
      and can be used to predict IVIg resistance.
  - reference: PMID:33413220
    supports: SUPPORT
    snippet: In comparison between KDSS and TSS, patients with KDSS had a
      significantly higher erythrocyte sedimentation rate (ESR) and
      significantly lower creatinine.
    explanation: The study shows that patients with Kawasaki Disease Shock
      Syndrome (KDSS) have significantly higher ESR levels.
  - reference: PMID:15677370
    supports: SUPPORT
    snippet: The erythrocyte sedimentation rate (ESR) increased significantly 24
      h after IVIG, and the elevated level was sustained for 7 days.
    explanation: This reference shows that ESR levels are elevated during the
      acute stage of Kawasaki Disease.
- name: Platelet Count
  presence: Elevated
  context: Often seen in the subacute phase
  evidence:
  - reference: PMID:33527178
    supports: SUPPORT
    snippet: In Kawasaki disease (KD), thrombocytosis is commonly found in the
      subacute phase.
    explanation: The abstract states that thrombocytosis (elevated platelet
      count) is commonly found in the subacute phase of Kawasaki disease.
  - reference: PMID:6833960
    supports: SUPPORT
    snippet: The second, subacute, phase begins with a decline of the acute
      findings and proceeds with desquamation of rash, joint manifestations,
      thrombocytosis, and cardiac disease.
    explanation: The text explicitly mentions that thrombocytosis occurs during
      the subacute phase of Kawasaki disease.
diagnosis:
- name: Echocardiogram
  description: Cardiac ultrasound to detect coronary artery dilation, aneurysms,
    and other cardiac abnormalities.
  notes: Used to check for coronary artery involvement
  evidence:
  - reference: PMID:28921836
    supports: SUPPORT
    snippet: Echocardiography is an excellent noninvasive imaging modality for
      evaluation and follow-up of cardiac lesions, especially coronary artery
      changes occurring as a result of Kawasaki disease.
    explanation: The reference clearly states that echocardiography is used to
      evaluate coronary artery changes in Kawasaki disease, supporting the
      statement.
- name: Blood Tests
  description: Laboratory assessment including CRP, ESR, platelet count, and
    white blood cell count to evaluate inflammation.
  notes: Elevated inflammatory markers (CRP and ESR)
  evidence:
  - reference: PMID:36569014
    supports: PARTIAL
    snippet: Since KD is a disease caused by arterial inflammation, many
      patients with KD have elevated levels of inflammatory biomarkers, such as
      C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and serum
      amyloid A protein (SAA) in blood tests.
    explanation: The literature suggests that many patients with Kawasaki
      Disease have elevated inflammatory markers, but it also reports cases
      where such elevations are not observed.
  - reference: PMID:34854940
    supports: SUPPORT
    snippet: Thrombocytosis, conjunctivitis, and oral and/or pharyngeal erythema
      and/or strawberry tongue were associated with higher rates of
      echocardiographic abnormalities.
    explanation: The study indicates that inflammatory markers are associated
      with echocardiographic abnormalities in Kawasaki Disease, supporting the
      statement.
  - reference: PMID:33481812
    supports: SUPPORT
    snippet: We obtained eight independent predictors (platelets, eosinophil,
      alanine aminotransferase, C-reactive protein, hemoglobin, mean corpuscular
      hemoglobin, mean corpuscular hemoglobin concentration, and monocyte).
    explanation: CRP is identified as one of the independent predictors for
      Kawasaki Disease, supporting the statement.
  - reference: PMID:27881022
    supports: SUPPORT
    snippet: YKL-40 concentration in the serum of KD patients significantly
      increased during the acute disease phase compared with those of disease
      controls and healthy controls.
    explanation: The study supports the presence of elevated inflammatory
      markers in Kawasaki Disease patients.
  - reference: PMID:37188888
    supports: SUPPORT
    snippet: PK2 can significantly predict Kawasaki disease independently of CRP
      and ESR (p &lt; 0.0001).
    explanation: CRP and ESR are mentioned as markers that can independently
      predict Kawasaki Disease, supporting the statement.
genetic:
- name: ITPKC
  association: Risk variant reduces negative regulation of Ca2+/NFAT signaling
    leading to enhanced T-cell activation
  notes: Associated with coronary lesions and hyperinflammation; rationale for
    calcineurin inhibitors
- name: FCGR2A
  association: Mediates immune-complex driven neutrophil/monocyte activation
  notes: Mechanistic basis for IVIG competing at FcŒ≥Rs; genetic association with
    susceptibility
- name: FCGR3A
  association: Mediates immune-complex driven neutrophil/monocyte activation
  notes: Involved in FcŒ≥R signaling and immune complex handling
- name: BLK
  association: B lymphoid tyrosine kinase involved in B-cell receptor signaling
  notes: Genetic locus implicated in altered B-cell/plasmablast responses
- name: CD40
  association: Promotes B/T cell and endothelial activation via CD40-CD40L
    co-stimulation
  notes: CD40L on T cells linked to endothelial cell activation and inflammation
- name: HLA-B
  association: HLA associations support antigen-driven or superantigen-like
    T-cell responses
  notes: Shapes disease susceptibility; useful for dissecting trigger(s) and
    host response subtypes
- name: CASP3
  association: Implicated in endothelial cell apoptosis and vascular remodeling
    during acute vasculitis
  notes: Apoptosis modulation is investigational
- name: ORAI1
  association: Store-operated calcium entry component; variants alter SOCE
    leading to dysregulated Ca2+ signaling
  notes: Heightened T-cell responses contribute to hyperinflammation
- name: STIM1
  association: Store-operated calcium entry component; variants alter SOCE
    leading to dysregulated Ca2+ signaling
  notes: Points to SOCE or calcineurin/NFAT modulation as therapeutic option
- name: TGFBR2
  association: TGF-Œ≤ receptor involved in endothelial-to-mesenchymal transition
  notes: Drives EndMT and luminal myofibroblast proliferation leading to
    stenosis/aneurysm formation
- name: SMAD3
  association: TGF-Œ≤ signaling mediator involved in vascular remodeling
  notes: Anti-fibrotic or TGF-Œ≤ pathway modulation is theoretical target
- name: TGFB2
  association: TGF-Œ≤ signaling involved in chronic vascular remodeling
  notes: Informs long-term vascular remodeling targets
- name: IL1B
  association: IL-1Œ≤ promotes endothelial injury, inflammation and remodeling
  notes: Direct IL-1 blockade (anakinra) has mechanistic and clinical rationale
    for IVIG-resistant KD
- name: IL1R1
  association: IL-1 receptor; downstream of inflammasome activation
  notes: IL-1 pathway is therapeutic target
- name: TNF
  association: Induces endothelial cell expression of ICAM-1/VCAM-1, iNOS and
    proinflammatory cascade
  notes: Anti-TNF therapy (infliximab) used for IVIG-resistant cases
- name: IL17A
  association: Th17 expansion and elevated IL-17 associate with coronary damage
    and IVIG resistance
  notes: Promotes neutrophil recruitment; IL-17/IL-23 pathway inhibitors are
    investigational
- name: IL23A
  association: IL-23 involved in Th17 axis and IL-17 signaling
  notes: Potential investigational approach in select patients
- name: NLRP3
  association: NLRP3 inflammasome activation leads to IL-1Œ≤ release and
    pyroptosis
  notes: NLRP3 or IL-1 pathway inhibition offers mechanistic target
- name: NOS3
  association: Reduced eNOS expression/activity leads to decreased NO,
    vasoconstriction, and thrombosis
  notes: Supports vascular-protective strategies and monitoring of endothelial
    function
- name: ICAM1
  association: Upregulated by TNF/IL-1 leading to leukocyte recruitment and
    endothelial dysfunction
  notes: Adhesion-inflammation axis is biomarker and potential target
- name: VCAM1
  association: Upregulated by TNF/IL-1 leading to vascular injury
  notes: Part of adhesion-inflammation axis
treatments:
- name: Intravenous Immunoglobulin (IVIG)
  description: First-line treatment to reduce inflammation and risk of coronary
    artery complications.
  evidence:
  - reference: PMID:23283289
    supports: SUPPORT
    snippet: Intravenous immunoglobulin (IVIG) and aspirin is the standard
      initial therapy in the treatment of Kawasaki disease.
    explanation: The literature confirms that IVIG is part of the standard
      initial therapy for Kawasaki disease, aimed at reducing inflammation and
      preventing coronary artery complications.
  - reference: PMID:38135926
    supports: SUPPORT
    snippet: For KD patients, male, children aged 3 to 9 years, and those with
      fever longer than 6 days before intravenous immunoglobulin (IVIG) use were
      more likely to have CAL.
    explanation: The study discusses the use of IVIG and its timing in relation
      to the risk of coronary artery lesions, supporting its role in reducing
      such risks.
  - reference: PMID:24034380
    supports: SUPPORT
    snippet: The standard of care for treatment is intravenous immunoglobulin
      plus aspirin, but adding corticosteroids may provide additional benefit
      for high-risk patients.
    explanation: The literature states that IVIG is the standard of care for
      treating Kawasaki disease to reduce coronary artery complications.
  - reference: PMID:34535199
    supports: SUPPORT
    snippet: Intravenous immunoglobulin (IVIG) has become an effective treatment
      regimen, which can effectively reduce the incidence of cardiovascular
      complications.
    explanation: The literature confirms that IVIG is effective in reducing
      cardiovascular complications in Kawasaki disease.
  - reference: PMID:32888683
    supports: SUPPORT
    snippet: Treatment of Kawasaki disease (KD) with intravenous immunoglobulin
      (IVIG) administered within the initial 10 days of fever onset decreases
      the risk of coronary artery aneurysms (CAAs) from ‚àº 25% to less than 5%.
    explanation: The literature provides evidence that IVIG significantly
      reduces the risk of coronary artery complications when administered early.
  treatment_term:
    preferred_term: pharmacotherapy
    description: Treatment of disease through the administration of medications.
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Aspirin
  description: Used in high doses for its anti-inflammatory and antipyretic
    effects, followed by a lower dose to prevent blood clots.
  evidence:
  - reference: PMID:9513217
    supports: SUPPORT
    snippet: Treatment includes the hospitalization of the child and subsequent
      administration of high doses of aspirin and intravenous immunoglobulin.
      With recovery, aspirin doses are reduced and the child may be monitored at
      home with outpatient follow-up.
    explanation: This reference confirms that high doses of aspirin are used
      initially for Kawasaki disease, followed by lower doses after recovery.
  - reference: PMID:10935427
    supports: SUPPORT
    snippet: Conventional therapy for KD includes intravenous gammaglobulin (2
      g/kg as a single dose over 12 hours) and aspirin (acetylsalicylic acid;
      high dose until the fourteenth day of illness then low dose).
    explanation: This reference also supports the statement that high doses of
      aspirin are used initially, followed by lower doses.
  - reference: PMID:32159800
    supports: PARTIAL
    snippet: Low-dose aspirin plus IVIG might be as effective as high-dose
      aspirin plus IVIG for the initial treatment of Kawasaki disease.
      Considering that high-dose aspirin may cause more adverse reactions than
      low-dose aspirin, low-dose aspirin plus IVIG should be recommended as the
      first-line therapy in the initial treatment of Kawasaki disease.
    explanation: This reference suggests that low-dose aspirin might be equally
      effective as high-dose aspirin and should be recommended to avoid adverse
      reactions, indicating a shift in treatment preference.
  - reference: PMID:28043685
    supports: PARTIAL
    snippet: The use of medium- or higher-dose ASA in acute Kawasaki disease did
      not prevent CAA. A future randomized controlled trial is needed to
      determine the optimum dose of ASA.
    explanation: This reference indicates that higher doses of aspirin did not
      prevent coronary artery aneurysms and suggests the need for further
      research to determine the optimal dose.
  treatment_term:
    preferred_term: cardiovascular agent therapy
    description: Treatment using medications that affect the cardiovascular
      system, including antiplatelet agents.
    term:
      id: MAXO:0000181
      label: cardiovascular agent therapy
- name: Anakinra
  description: IL-1 receptor antagonist used for IVIG-resistant Kawasaki disease
    to block IL-1-mediated endothelial injury.
  notes: Mechanistic rationale based on NLRP3 inflammasome and IL-1Œ≤ pathway
    activation
  treatment_term:
    preferred_term: pharmacotherapy
    description: Treatment using IL-1 pathway inhibition for refractory
      inflammation.
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Cyclosporine
  description: Calcineurin inhibitor used to modulate Ca2+/NFAT signaling in
    genetically susceptible patients.
  notes: Targets dysregulated calcium signaling pathway; used for IVIG-resistant
    cases
  treatment_term:
    preferred_term: pharmacotherapy
    description: Treatment using calcineurin inhibition to reduce T-cell
      activation.
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Corticosteroids
  description: Used in cases resistant to IVIG or with severe inflammation.
  evidence:
  - reference: PMID:31914832
    supports: SUPPORT
    snippet: We suggest using methylprednisolone pulse therapy as an alternative
      rescue therapy for immunoglobulin-resistant KD, as well as identifying
      high-risk patients who need initial corticosteroid with IVIG treatment
      with an adequate route, dose, and duration.
    explanation: The literature supports the use of corticosteroids in cases of
      Kawasaki Disease that are resistant to IVIG or in high-risk patients with
      severe inflammation.
  - reference: PMID:29101553
    supports: SUPPORT
    snippet: &#39;&#34;Resistant&#34; Kawasaki disease is defined by the American Heart Association
      as failure to respond within 36 h following the first dose of intravenous immunoglobulin.
      The optimal management of resistant Kawasaki disease remains uncertain, the
      outcomes are potentially serious, and the cost of some treatments is considerable.&#39;
    explanation: This reference discusses the management of resistant Kawasaki
      Disease, which includes considering corticosteroid use.
  - reference: PMID:33541111
    supports: SUPPORT
    snippet: To prevent CAA, more intensified or adjunctive therapies using
      other agents, such as pulsed methylprednisolone, ciclosporin, infliximab,
      and Anakinra, should be considered for patients with these risk factors.
    explanation: This reference mentions the use of pulsed methylprednisolone (a
      corticosteroid) for patients with Kawasaki Disease who are at risk of
      developing coronary artery abnormalities, indicating severe inflammation.
  treatment_term:
    preferred_term: pharmacotherapy
    description: Treatment using corticosteroids to reduce inflammation in
      refractory cases.
    term:
      id: MAXO:0000058
      label: pharmacotherapy
notes: Prompt treatment is crucial to prevent coronary artery complications.
  Long-term follow-up may be necessary for some patients.
disease_term:
  preferred_term: Kawasaki disease
  description: An acute febrile vasculitis of childhood primarily affecting
    medium-sized arteries with risk of coronary artery complications.
  term:
    id: MONDO:0012727
    label: mucocutaneous lymph node syndrome
classifications:
  harrisons_chapter:
  - classification_value: cardiovascular disorder
  - classification_value: immune system disorder
references:
- reference: DOI:10.1016/j.pedneo.2023.05.002
  title: Pathophysiological and clinical point of view on Kawasaki disease and
    MIS-C
  findings: []
- reference: DOI:10.1111/1756-185x.14816
  title: &#39;An update on understanding the &lt;scp&gt;pathophysiology&lt;/scp&gt; in Kawasaki disease:
    Possible role of immune complexes in coronary artery lesion revisited&#39;
  findings: []
- reference: DOI:10.1172/jci176938
  title: The etiologies of Kawasaki disease
  findings: []
- reference: DOI:10.3389/fimmu.2024.1323171
  title: FCGR2/3 polymorphisms are associated with susceptibility to Kawasaki
    disease but do not predict intravenous immunoglobulin resistance and
    coronary artery aneurysms
  findings: []
- reference: DOI:10.3389/fped.2024.1415941
  title: Research perspective in the clinical management of Kawasaki disease
  findings: []
- reference: DOI:10.3390/ijms252413322
  title: &#39;Endothelial Dysfunction: Molecular Mechanisms and Therapeutic Strategies
    in Kawasaki Disease&#39;
  findings: []
- reference: DOI:10.52533/johs.2024.40109
  title: Etiology, Pathophysiology, Diagnosis and Management of Kawasaki Disease
  findings: []
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Kawasaki_Disease.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>